Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Congress Ends Shutdown, Clinches Two-Year Device-Tax Repeal

Executive Summary

Congress reached agreement Jan. 22 to end the three-day US government shutdown in a continuing resolution bill that includes a two-year device-tax suspension.

You may also be interested in...



Fixing Reimbursement ‘Valley Of Death’ And Repealing The Device Tax Are Top MDMA Priorities, CEO Leahey Says

In an interview about medical device lobbying priorities, the Medical Device Manufacturers Association CEO Mark Leahey talked about efforts to figure out administrative and potentially legislative solutions to gain reimbursement for products sooner after FDA approval. Leahey also argues industry groups are in a better position to permanently repeal the 2.3% medical device excise tax despite previous failures to do so.

As US FDA Shutdown Continues, What Will Be The Cost Of Not Spending?

Bolus of applications could be filed once government reopens, but employee morale and recruitment efforts could suffer drop-off.

House-Passed Tax Bill Would Support Medtech Innovation, Lobbyists Say

The device industry is praising passage of “The American Innovation Act” by the US House. The bill is intended to promote new business start-ups – including fledgling medtech companies – by allowing certain tax deductions for net-operating losses.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT122078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel